Predictive Oncology Inc. POAI Archives - Page 19 of 19

WednesdayOct 02, 2019 9:26 am

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Prices Public Offering; Subsidiary Sells 10 STREAMWAY Systems to Leading Teaching Hospital in New York

Predictive Oncology (NASDAQ: POAI) today announced pricing for the public offering of its common stock that the company announced in a news release on Tuesday. The company is offering 6,335,537 shares on a “best efforts” basis at a price of $0.50 each for anticipated gross proceeds of up to $3,167,768.50, before subtracting placement agent fees, expenses and offering expenses payable by POAI. Dawson James Securities, Inc. and Paulson Investment Company, LLC are acting as exclusive placement agents for the offering. Subject to customary closing conditions, the offering is projected to close on or about October 4, 2019. In addition, Predictive…

TuesdayOct 01, 2019 12:37 pm

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Participates in UK 100,000 Genomes Project

The main subsidiary of POAI partnered with Genomics England for the groundbreaking UK 100,000 Genomes Project POAI is positioned on the cutting edge of future cancer treatments The company’s AI-driven platforms are improving cancer patient outcomes and setting a new standard in the industry For years, cancer treatment has involved human beings playing the role of guinea pigs. Oncologists have become quite adept at diagnosing specific types of cancer, but they mostly lack the data to know which drugs will be most effective in fighting patients’ specific cancer types. Patients leave doctors’ offices hopeful but worried, gambling their recovery on…

TuesdayOct 01, 2019 9:27 am

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Executes Repayments, Extensions of Promissory Notes

Predictive Oncology (NASDAQ: POAI) on Monday announced that it repaid or extended the secured promissory notes that were due September 28, 2019. POAI repaid the remaining principal and interest balance of $478,590 on one note on September 27th. The company also secured a new investment of $700,000 from a private investor in exchange for a new 8% secured promissory note due on March 27, 2020 with an original principal amount of $847,500. POAI issued 88,574 shares of common stock and a 682,368 share warrant to the new investor. The company also amended the other outstanding note to extend the maturity…

FridaySep 27, 2019 3:18 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Bringing Precision Medicine Tools to Physicians

Predictive Oncology (NASDAQ: POAI) is assisting clinicians and researchers in improving outcomes for cancer patients via its AI-driven, tumor-profiling platform. A recent article discussing the company reads, “POAI’s technology combines its database of evidence documenting actual drug responses of cancer patients’ tumors with artificial intelligence (AI) to create an invaluable predictive tool for clinicians and researchers. Predictive Oncology’s data offers a valuable, customizable assessment method that can be used by oncologists to determine the best drug for fighting a specific patient’s cancer. This disruptive technology is the first of its kind and is also meeting a critical need in the…

FridaySep 20, 2019 1:48 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Transforming Cancer-Treatment Outcomes via Proprietary Database

Predictive Oncology (NASDAQ: POAI) is taking a unique approach to cancer treatment by utilizing its proprietary database of cancer cases using the proven power of artificial intelligence (“AI”). A recent article discussing the company reads, “The company works alongside pharmaceutical, diagnostic and biotechnology industry players to develop highly customizable assessment methods that can be applied to both individualize current therapies and develop the next generation of precision therapies, leading to better outcomes for patients. The company recently announced a corporate name change from Precision Therapeutics to Predictive Oncology Inc., which reflects its mission and strategic emphasis. . . . Predictive…

ThursdaySep 19, 2019 11:56 am

Predictive Oncology Inc. (NASDAQ: POAI) Uses Smart Tumor Profiling Platform with AI to Bring Value to Pharmaceutical, Biotech Industries

POAI’s artificial intelligence (AI)-driven tumor profiling platform brings precision medicine tools to clinicians and researchers to improve cancer outcomes The company holds a critical strategic advantage over mammoth competitors, attracting investor attention POAI is committed to providing sophisticated tools to help select current therapies more precisely and develop new targeted therapies Predictive Oncology Inc. (NASDAQ: POAI) is working with the pharmaceutical and biotech industries to offer an AI-driven tumor profiling platform that clinicians and researchers can use to improve outcomes for cancer patients of today and tomorrow. POAI has built a distinctly valuable asset in its existing base of drug-response…

WednesdaySep 18, 2019 12:01 pm

Predictive Oncology Inc. (NASDAQ: POAI) Utilizes Proprietary Dataset to Revolutionize Treatment Outcomes for Cancer

Predictive Oncology is working to develop highly customizable assessment methods to individualize treatment options for cancer, improving outcomes POAI’s innovative technology is pioneering in the field of individualizing treatment for ovarian cancer Predictive Oncology offers potential for significant ROI as it focuses on improving outcomes for cancer patients of today and tomorrow Predictive Oncology Inc. (NASDAQ: POAI) is harnessing its unique, proprietary database of cancer cases using the proven power of artificial intelligence (AI) to revolutionize treatment outcomes for cancer patients. The company works alongside pharmaceutical, diagnostic and biotechnology industry players to develop highly customizable assessment methods that can be…

FridaySep 06, 2019 2:14 pm

QualityStocksNewsBreaks – Why Predictive Oncology Inc. (NASDAQ: POAI) Is ‘One to Watch’

Data and artificial intelligence-driven discovery services company Predictive Oncology (NASDAQ: POAI) provides predictive models of tumor drug response to improve patient outcome. A recent article discussing the company reads, “Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based road map for therapy. . . . In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that…

TuesdaySep 03, 2019 11:44 am

Predictive Oncology Inc. (NASDAQ: POAI) is “One to Watch”

Helomics is collaborating with the University of Pittsburgh School of Medicine to study the use of artificial intelligence to improve clinical decision making for ovarian cancer patients. More than 22,000 women are diagnosed with ovarian cancer in the U.S. each year. Entered an agreement with Interpace Diagnostics Group Inc. (IDXG) and Helomics to develop products to diagnose and assess the risk for thyroid cancer as well as provide appropriate therapeutic recommendations. The treatment market for thyroid cancer is expected to reach $2.1 billion by 2025. Skyline Medical has received its first order for four STREAMWAY machines to be sold to…

Site Search

Company Search

Tag: Predictive Oncology Inc. POAI